UPB Upstream Bio, Inc.
Company Analysis
Latest News
Upstream Bio's third quarter 2026 revenue missed estimates while Phase 3 remains on track for 2027
Upstream Bio reported collaboration revenue of $0.40 million and a net loss of $41.2 million for the third quarter of 2026, as the clinical-stage biotech...
Upstream Bio, Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 11, 2026
Analysts expect Upstream Bio to report Q3 2026 revenue of approximately $0.53 million and a net loss of $0.73 per share, while the stock currently trades at...
Upstream Bio, Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
For the third quarter of 2026, analysts anticipate Upstream Bio will report a loss of $0.73 per share on revenue of approximately $0.52 million, with its...
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug
Upstream Bio (UPB) announced its pivotal Phase 3 development plans for its drug candidate, verekitug, for the treatment of severe asthma and chronic...
Upstream Bio second quarter 2026 results highlight $261M cash runway and 2027 Phase 3 targets
Upstream Bio reported a net loss of $39.7 million and collaboration revenue of $0.8 million for the second quarter ended June 30, 2026. The company is...
Upstream Bio, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Upstream Bio, Inc. is expected to report a Q2 2026 loss of $0.78 per share on zero revenue, with the stock currently trading at $32.45 against a consensus...
🔴 Upstream Bio, Inc. is trading 9.9% down today on volatility tied to clinical trial data and gene-therapy sentiment
Upstream Bio, Inc. is trading 9.9% down at $7.28 following a sharp intraday selloff despite a lack of new company-specific news or SEC filings. • The decline...
🔴 Upstream Bio, Inc. is trading 10.2% down today after sharp intraday selloff on no specific news
Upstream Bio, Inc. is trading at $7.26 (10.2% down) following a sharp intraday selloff, despite no new confirmed company-specific news or SEC filings hitting...
🔴 Upstream Bio, Inc. is trading 9.6% down today following a sharp intraday selloff
Upstream Bio, Inc. is trading 9.6% down at $7.30 on June 2, 2026, following a sharp intraday selloff despite a lack of new confirmed company-specific news or...